Infixion is awarded third NIH SBIR phase 1 grant to develop therapeutics for NF1

Infixion announced its third NIH SBIR Phase 1 grant from the National Institute of Neurological Disorders and Stroke (NINDS). Infixion has received two previous NIH SBIR Phase 1 grants for NF1 drug discovery (2020 and 2021), and this third NIH grant will enable Infixion to further advance efforts to correct for the lack of normal NF1 protein (called neurofibromin), a critical regulatory protein that is lacking in people living with NF1.

Infixion’s three NIH grants all focus on developing gene-targeted therapeutics impacting the NF1 protein life-cycle, providing a multipronged drug discovery effort.  In parallel, Infixion is advancing the development of scientific tools for NF1, such as a new monoclonal antibody to detect and measure NF1 protein, supporting further NF1 research community collaboration.  Herb Sarnoff, Infixion’s CEO and NF1 ‘dadvocate’, noted: “We are very proud to have the continued support and confidence of the NIH to help Infixion’s ongoing research to develop a revolutionary treatment for people living with NF1, and to support the NF1 research community wherever possible.”

The mission of Infixion Bioscience is to discover and develop therapeutics that radically improve the lives of people living with Neurofibromatosis Type 1.

Read the full press release here.